Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
09.02.2022 - Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Cenexi, a French CDMO specializing in the formulation, analytical ... Seite 1
Source: wallstreet-online.de